Table 3.
Pharmacokinetic parameters (mean ± SEM) derived from plasma concentration-time profiles following the administration of IV bolus (4 mg/kg), oral lipid-free formulation (12 mg/kg), and long chain triglyceride (LCT)-based formulation (12 mg/kg) of cannabidiol (CBD) to rats
| Administration/formulation | AUC0-t (h.ng/mL) | Vd (mL/kg) | CL (mL/h/kg) | t 1/2 (h) | Cmax (ng/mL) | Tmax (h) | F (%) | n |
|---|---|---|---|---|---|---|---|---|
| IV bolus | 1380 ± 43 | 12495 ± 2607 | 2794 ± 85 | 2.0 ± 0.1 | - | - | - | 4 |
| Oral lipid-free | 327 ± 91 | - | - | 2.5 ± 0.4 | 87 ± 25 | 3 | 7.9 ± 2.2 | 4 |
| Oral LCT-based | 932 ± 188* | - | - | 1.6 ± 0.1 | 308 ± 109 | 3 | 22.3 ± 4.6* | 4 |
Unpaired t-test was used for statistical analysis.
*
Statistically different from oral lipid-free formulation (P < 0.05).